Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration

• Status: Terminated
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of dexamethasone (OZURDEX®) as adjunctive therapy to ranibizumab (LUCENTIS®) compared with ranibizumab alone in the treatment of patients with choroidal neovascularization secondary to age-related macular degeneration

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Ranibizumab

Criteria

Inclusion Criteria:

• Received at least 2 and no more than 3 monthly Lucentis or Avastin injections

• Last Lucentis or Avastin was injected approximately 4 weeks prior to screening

• Visual acuity between 20/320 and 20/40

Exclusion Criteria:

• Active ocular infection

• Contraindication to pupil dilation in either eye

• Eye surgery including cataract surgery and/or laser of any type within 3 months